The Affordable Care Act (ACA) has experienced challenges in the current open enrollment season, with new and returning sign-ups nearly half of last year’s rate. Furthermore, a court ruling blocked enrollment of “dreamers” (DACA recipients) under the ACA. Although the ruling was temporarily stayed, the final decision is pending appeal. The Biden administration argues against the ruling, citing disruption and more costs for the federal government.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
